Angion Enrolls First Patients in Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia

    NEXT STORY
    Valneva Reports H1 Results Marked by Major Corporate Achievements and Strong Cash Position
    PREV STORY
    ORIC Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Global Blood Testing Market Size, Share & Trends, Analysis & Forecasts, 2016-2019 & 2020-2027

    author_avatar
    NASDAQ Market News

    Summit Therapeutics Announces Novel Antibiotic Ridinilazole (SMT19969) Achieves Statistical Superiority Over Vancomycin in CoDIFy Phase 2 Clinical Trial for C. difficile Infection

    Sustained Clinical Response Rates of 66.7% with Ridinilazole vs. 42.4% with Vancomycin Ridinilazole to ...

    author_avatar
    NASDAQ Market News

    Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil. to its Board of Directors

    BOSTON, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage ...

    author_avatar
    NASDAQ Market News